EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson’s disease: A randomized double-blind placebo-controlled trial

Yu Zhang, Xiao-Bo Zhu, Yang Zhao, Gui-Yun Cui, Wen-Tao Li, Can-Xing Yuan, Jian-Ping Huang, Ying Wan, Na Wu, Lu Song, Jia-Hao Zhao, Yan Liang und 5 weitere

Journal of Integrative Medicine · 2024-09 · 22 (5) · 545-551

DOI: 10.1016/j.joim.2024.07.002 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Integrative Medicine, 2024-09. Verfasst von Yu Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China. Hauptthemen laut MEDLINE: Amantadine, Drugs, Chinese Herbal, Dyskinesia, Drug-Induced, Levodopa. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with Parkinson's disease (PD) undergoing long-term levodopa therapy are prone to develop levodopa-induced dyskinesia (LID). Amantadine is the main drug recommended for the treatment of LID by current guidelines, but it is far from meeting clinical needs. Tianqi Pingchan Granule (TPG), a compound Chinese herbal medicine, has been developed to relieve symptom of LID. OBJECTIVE: This randomized controlled trial evaluated the efficacy and safety of the combination of TPG and amantadine for LID. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: This is a randomized double-blind placebo-controlled trial, conducted from January 2020 to August 2021 at 6 sites in Jiangsu, Zhejiang and Shanghai, China. One hundred PD patients with ≥ 0.5 h of LID were randomly assigned to either the TPG plus amantadine group (TPG group) or the placebo plus amantadine group (placebo group), and treated for a period of 12 weeks. To ensure unbiased results, all study participants, investigators and sponsors were unaware of group allocations. Additionally, the data analysts remained blinded until the analysis was finalized. MAIN OUTCOME MEASURES: The primary outcome was assessed using the Unified Dyskinesia Rating Scale (UDysRS) (Range 0-104). The key secondary end point was improvement of motor and non-motor symptoms. Safety analyses included all enrolled patients. RESULTS: One hundred patients were enrolled and randomized into the two treatment groups. The changes in UDysRS at week 12 were -11.02 for the TPG group and -4.19 for the placebo group (treatment difference -6.83 [-10.53 to -3.12]; P = 0.0004). Adverse events were reported for 2 of 50 patients (4.0%) in each of the groups. CONCLUSION: This study indicated that a 12-week treatment of amantadine plus TPG effectively reduced UDysRS scores and was well tolerated, demonstrating the efficacy and safety of TPG for the treatment of LID in PD. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04173832. PLEASE CITE THIS ARTICLE AS: Zhang Y, Zhu XB, Zhao Y, Cui GY, Li WT, Yuan CX, Huang JP, Wan Y, Wu N, Song L, Zhao JH, Liang Y, Xu CY, Liu MJ, Gao C, Chen XX, Liu ZG. Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson's disease: A randomized double-blind placebo-controlled trial. J Integr Med. 2024; 22(5): 545-551.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmantadineDrugs, Chinese HerbalDyskinesia, Drug-InducedLevodopaParkinson DiseaseAgedFemaleHumansMaleMiddle AgedAntiparkinson AgentsDouble-Blind MethodDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

Levodopa-induced dyskinesiaParkinson’s diseaseTianqi Pingchan Granule

Substanzen

AmantadineAntiparkinson AgentsDrugs, Chinese HerbalLevodopa

Autor:innen und Institutionen

  • Department of Neurology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
  • Department of Neurology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, Jiangsu Province, China.
  • Parkinson's Disease Center, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China.
  • Department of Neurology, Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.
  • Department of Neurology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
  • Department of Neurology, Wenzhou Central Hospital, Wenzhou 325000, Zhejiang Province, China.

Zitieren

APA

Zhang, Y., Zhu, X. B., Zhao, Y., Cui, G. Y., Li, W. T., Yuan, C. X., Huang, J. P., Wan, Y., Wu, N., Song, L., Zhao, J. H., Liang, Y., Xu, C. Y., Liu, M. J., Gao, C., Chen, X. X., & Liu, Z. G. (2024). Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson’s disease: A randomized double-blind placebo-controlled trial. Journal of Integrative Medicine, 22(5), 545-551. https://doi.org/10.1016/j.joim.2024.07.002

Vancouver

Zhang Y, Zhu XB, Zhao Y, Cui GY, Li WT, Yuan CX, et al. Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson’s disease: A randomized double-blind placebo-controlled trial. Journal of Integrative Medicine. 2024;22(5):545-551. doi:10.1016/j.joim.2024.07.002

BibTeX
@article{Zhang2024,
  author = {Zhang, Yu and Zhu, Xiao-Bo and Zhao, Yang and Cui, Gui-Yun and Li, Wen-Tao and Yuan, Can-Xing and Huang, Jian-Ping and Wan, Ying and Wu, Na and Song, Lu and Zhao, Jia-Hao and Liang, Yan and Xu, Chuan-Ying and Liu, Mei-Juan and Gao, Chen and Chen, Xin-Xin and Liu, Zhen-Guo},
  title = {Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson’s disease: A randomized double-blind placebo-controlled trial},
  journal = {Journal of Integrative Medicine},
  year = {2024},
  volume = {22},
  number = {5},
  pages = {545--551},
  doi = {10.1016/j.joim.2024.07.002}
}
Kostenlos starten →